Author

C. Lam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Cancer Biology· 2 Biochemistry· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Approach:statistical model· 5 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:variant calling· 3 Organism:virus· 3 Assay:whole-genome sequencing· 3

Frequent Co-Authors

V. Sintchenko· 5 shared A. Arnott· 4 shared J. Kok· 4 shared K. Basile· 4 shared R. J. Rockett· 4 shared D. C. Ekiert· 3 shared D. E. Dwyer· 3 shared G. Bhabha· 3 shared

Activity by Year

2017-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

V. Sintchenko

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

scRNA-seq reveals transcriptional dynamics of Encephalitozoon intestinalis parasites in human macrophages

P. Jaroenlak, K. L. McCarty, B. Xia, C. Lam, E. E. Zwack, I. Yanai, G. Bhabha, D. C. Ekiert

This study uses scRNA-seq to analyze transcriptional changes in human macrophages and Encephalitozoon intestinalis parasites during infection, revealing parasite developmental dynamics and host response.

bioRxiv · May 30, 2024 · PreprintMicrobiology

Genomic evolution of SARS-CoV-2 variants of concern under in vitro neutralising selection pressure following two doses of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine

K. Basile, J. E. Agius, W. Fong, K. McPhie, M. Fennel, D. Ko, L. Hueston, C. Lam, A. Arnott, S. C.-A. Chen, S. Maddocks, M. V. N. O Sullivan, D. Dwyer, V. Sintchenko, J. Kok, , CIDMLS COVID-19 Study Group

This study assesses the neutralizing antibody titres against SARS-CoV-2 variants Delta and Beta post-Pfizer-BioNTech vaccination, finding significant reductions compared to wild-type virus.

bioRxiv · Sep 24, 2023 · PreprintMicrobiology

3D reconstructions of parasite development and the intracellular niche of the microsporidian pathogen E. intestinalis

N. V. Antao, C. Lam, A. Davydov, M. Riggi, J. Sall, C. Petzold, F.-X. Liang, J. Iwasa, D. C. Ekiert, G. Bhabha

This study uses 3D imaging to analyze the development of the microsporidian E. intestinalis and its interaction with host cell mitochondria.

bioRxiv · Jul 2, 2023 · PreprintMicrobiology

Genomic markers of drug resistance in Mycobacterium tuberculosis populations with minority variants

X. Zhang, C. Lam, E. Martinez, E. Sim, T. Crighton, B. J. Marais, V. Sintchenko

The paper identifies drug-resistant minority variants in Mycobacterium tuberculosis populations and shows their association with mixed strain populations and treatment outcomes.

bioRxiv · Apr 19, 2023 · PreprintMicrobiology

Protein-protein interactions in the Mla lipid transport system probed by computational structure prediction and deep mutational scanning

M. R. MacRae, D. Puvanendran, M. A. B. Haase, N. Coudray, L. R. Kolich, C. Lam, M. Baek, G. Bhabha, D. C. Ekiert

The paper maps protein-protein interactions in the Mla lipid transport system using deep mutational scanning and AlphaFold2 structure predictions, revealing overlapping binding sites on MlaC.

bioRxiv · Dec 9, 2022Biophysics

Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting

K. Basile, R. J. Rockett, K. McPhie, M. Fennell, J. Johnson-Mackinnon, J. Agius, W. Fong, H. Rahman, D. Ko, L. Donavan, L. Hueston, C. Lam, A. Arnott, S. Chen, S. Maddocks, , J. Kok

This study shows that Pfizer-BioNTech vaccine boosting increases neutralizing antibodies against Omicron, but they are still lower than against the A.2.2 lineage.

bioRxiv · Dec 12, 2021 · PreprintMicrobiology

SARS-CoV-2 Genome Sequencing Methods Differ In Their Ability To Detect Variants From Low Viral Load Samples

C. Lam, K.-A. Gray, M. Gall, R. Sadsad, A. Arnott, J. Johnson-Mackinnon, W. Fong, K. Basile, J. Kok, D. E. Dwyer, V. Sintchenko, R. J. Rockett

This study compares three SARS-CoV-2 sequencing methods for their ability to detect variants from low viral load samples, finding that ARTIC v3 is most sensitive.

bioRxiv · May 1, 2021Microbiology

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

I. D. Ferguson, Y.-H. T. Lin, C. Lam, H. Shao, M. Hale, K. M. Tharp, M. C. Mariano, V. Steri, D. Wang, P. Phojanokong, S. T. Tuomivaara, B. Hann, C. Driessen, B. V. Ness, J. E. Gestwicki, A. P. Wiita

This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.

bioRxiv · Apr 21, 2020Cancer Biology

REVEALING COVID-19 TRANSMISSION BY SARS-CoV-2 GENOME SEQUENCING AND AGENT BASED MODELLING

R. J. Rockett, A. Arnott, C. Lam, R. Sadsad, V. Timms, K.-A. Gray, J.-S. Eden, S. L. Chang, M. Gall, J. Draper, E. Sim, N. L. Bachmann, I. Carter, K. Basile, R. Byun, , V. Sintchenko

The paper uses SARS-CoV-2 genome sequencing and agent-based modeling to estimate local transmission rates during the early stages of the COVID-19 outbreak in New South Wales.

bioRxiv · Apr 19, 2020 · PreprintMicrobiology

Energy-dependent transport at dural lymphatic vessels is necessary for Aβ brain clearance in Alzheimer's disease

L. Romanova, H. Philips, G. Calip, K. Hauser, D. Peterson, O. Lazarov, D. Predescu, S. Predescu, J. Schneider, J. Kordower, E. Hansen, C. Lam, C. Janson

The paper shows that energy-dependent transport in dural lymphatic vessels is critical for clearing Aβ in Alzheimer's disease, and blocking this pathway accelerates Aβ pathology.

bioRxiv · Feb 5, 2019 · PreprintBiochemistry

Repurposing Tofacitinib As An Anti-Myeloma Therapeutic To Reverse Growth-Promoting Effects Of The Bone Marrow Microenvironment

C. Lam, M. Murnane, H. Liu, G. A. Smith, S. Wong, J. Taunton, J. O. Liu, C. S. Mitsiades, B. C. Hann, B. T. Aftab, A. P. Wiita

This paper validates tofacitinib as an effective anti-myeloma therapy by reversing bone marrow microenvironment-driven growth signals in vitro and in vivo.

bioRxiv · May 28, 2017Cancer Biology